Oncogenic MAP2K1 mutations in human epithelial tumors.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Scirrhous gastric cancer is an aggressive tumor subtype with a poor prognosis.
• Identifying the genetic drivers of this cancer is critical for developing effective therapies.

Purpose of the Study:

• To identify novel transforming genes in scirrhous gastric cancer.
• To investigate the role of identified mutations in cancer development and therapeutic targeting.

Main Methods:

• Construction of a complementary DNA (cDNA) expression library from scirrhous gastric cancer cells (OCUM-1).
• Focus formation assay using mouse 3T3 fibroblasts to identify transforming genes.
• Next-generation sequencing (deep sequencing) of MAP2K1 cDNA in human cancer specimens and cell lines.
• Treatment of cancer cells with a MAP2K1-specific inhibitor.

Main Results:

• Discovery of a transforming cDNA encoding MAP2K1 with a specific mutation (Q56P) in OCUM-1 cells.
• MAP2K1(Q56P) was essential for OCUM-1 cell transformation, as inhibiting MAP2K1 induced cell death.
• Deep sequencing identified six activating MAP2K1 mutations (including four novel ones) in 3.5% of 172 human epithelial tumor specimens/cell lines.
• The novel mutations (R47Q, R49L, I204T, P306H) conferred transforming potential to MAP2K1.

Conclusions:

• Activating mutations in MAP2K1 are present in a subset of human epithelial tumors, including scirrhous gastric cancer.
• Cancer cells with these MAP2K1 mutations exhibit addiction to elevated MAP2K1 activity for proliferation.
• MAP2K1 inhibitors represent a promising targeted therapy for human cancers harboring these specific MAP2K1 mutations.